GSK pays $10.6B for Nuvalent, a 40% premium pivot back to oncology
The U.K. pharma giant lands its biggest deal in eight years to rebuild a trimmed cancer pipeline.
By Turki Al-Mutairi·· 3 min
2 briefings · “oncology”
The U.K. pharma giant lands its biggest deal in eight years to rebuild a trimmed cancer pipeline.
GSK’s new CEO commits to a major oncology bet: the $10.6bn Nuvalent deal deepens its late-stage pipeline for lung cancer.